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Question under study: Cognitive impairment
occurs during multiple sclerosis (MS) and con-
tributes to the burden of the disease, but its effect
in the initial phase of MS still needs to be better
understood. 
Methods: We prospectively studied 127 early
MS patients presenting with a clinically isolated
syndrome (CIS) or definite MS, a mean disease
duration of 2.6 years, and with minor disability
(mean Expanded Disability Status Scale score
1.8). Patients were tested for long-term memory,
executive functions, attention, fatigue, mood dis-
orders, functional handicap and quality of life
(QoL). Twenty-one CIS patients were excluded
from study as the diagnosis of MS could not be
confirmed. 
Results: Over the 106 MS patients analysed,
31 (29.3%) were cognitively impaired (23.6% for
memory, 10.4% for attention and 5.7% for execu-
tive functions). Cognitive deficits were already
present in CIS patients in whom the diagnosis
was not yet confirmed (20%). Impaired cognition
was associated with anxiety (p = 0.05), depression
(p = 0.004), fatigue (p = 0.03), handicap (p <0.001)
and a lower QoL (p <0.001). After adjustment for
QoL, handicap, depression, anxiety and fatigue
were no longer associated with the presence of
cognitive deficits. 
Conclusions: In this well-defined early MS
group one third of the patients already exhibited
cognitive deficits, which were usually apparent in
an effortful learning situation and were generally
mild. Mood disorders, fatigue, handicap and de-
creased QoL were all associated with the occur-
rence of cognitive deficits. QoL itself appeared to
take all the other factors into account. Our results
confirm the existence of an interplay between
cognitive, affective and functional changes and fa-
tigue in early MS. 
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Summary
Cognitive deficits have been estimated to
occur in up to 70% of patients during the course
of multiple sclerosis (MS) [1]. The impairment
can affect a variety of cognitive functions, includ-
ing long-term and working memory [2, 3], inter-
hemispheric transfer, problem solving, executive
functions, speed of information processing and
attention [4, 5]. Such deficits have previously been
evidenced in early MS but the prevalences re-
ported were variable, ranging from 26% to more
than 53% depending on the study [6–8]. Incipient
cognitive deficits have also been assessed longitu-
dinally, suggesting that such deficits could be used
as predictive parameters of MS evolution and
severity [9–11]. Most of the MS patients’ samples
studied were, however, heterogeneous with re-
spect to MS duration and neurological disability,
and included either long-lasting or moderate to
severe MS subjects. Moreover, the sources of
transient symptoms, such as the interval before or
after relapses and the use of corticosteroids, as
well as the other pharmacological treatments al-
lowed at the time of testing, were not always re-
ported [6, 7]. 
Fatigue [12, 13] and mood disorders [14–16]
have also been suspected of contributing to a de-
cline in cognitive performance, but the relation-
ships between these factors and cognitive effi-
ciency are still poorly understood, especially in
early MS. The purpose of the present study was to
assess the prevalence of cognitive deficits and to
investigate the links between cognitive deficits
and MS patients’ functional handicap, fatigue,
mood disorders and quality of life (QoL) using a
well-defined sample of patients in the early phase
of MS.
Introduction
This work was
supported by
grants from the
Swiss Society for
Multiple Sclerosis
and the Swiss 
National Science
Foundation
(3200BO-104051,
to MS).
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The study population consisted of 127 patients with
a diagnosis of possible MS (i.e. clinically isolated syn-
drome [CIS]) or definite MS based on the revised Mc-
Donald criteria [17, 18]. Of these 127, 72 had relapsing
remitting (RR) MS, another 19 had experienced a single
relapse and showed dissemination in time and space
proven by magnetic resonance imaging (MRI; MRI
proven MS), while 36 had CIS with positive oligoclonal
bands in the cerebrospinal fluid and a positive MRI. Fif-
teen of these 36 CIS patients suffered a second relapse
during follow-up, thus confirming the diagnosis of MS
(mean interval to MS diagnosis confirmation 5.3 months,
SD 4.4), and were thus retained for analysis. 
To obtain a homogeneous population of early MS
patients, only patients with both a minor neurological
disability (Expanded Disability Status Scale [EDSS] 0–
2.5) [19], and a short MS duration (3 months–5 years)
were included. A minimum disease duration of 3 months
was stipulated on the basis of the revised McDonald cri-
teria [17, 18], which propose this time lapse following a
first neurological episode suggestive of MS before re-
peating a new brain MRI to prove subclinical dissemina-
tion of the inflammatory lesions over time. This allowed
us both to increase the proportion of patients with con-
firmed MS and to reduce as far as possible any influence
on cognitive functioning of transient mood dysregula-
tions related to the period close to the announcement of
MS diagnosis. A maximum MS duration of 5 completed
years was based on current knowledge of MS natural his-
tory. Patients receiving interferon-b1a and 1b, antide-
pressive drugs or amantadine as a symptomatic treatment
for fatigue were accepted. Inclusions were performed at
distance from exacerbations or corticosteroid treatment
(≥6 weeks). All MS patients included had previously
signed an informed consent form for participation in this
study, which had been approved by the local Ethics Com-
mittee.
Cognition
Neuropsychological testing focused on 3 cognitive
domains (long-term memory, executive functions and at-
tention) which are commonly impaired in MS. Norma-
tive data were available for all the tests used. The pres-
ence of a cognitive impairment was defined by a perform-
ance 2 standard deviations (SD) below the given mean for
a test. Long-term memory was assessed using Rey’s Audi-
tory Verbal Learning Test (RAVLT) [20], in which patients
are asked to learn a list of 15 words presented orally over
5 trials; delayed recall was then tested 40 minutes later.
Executive functioning was evaluated using the Behav-
ioural Assessment of the Dysexecutive Syndrome (BADS) [21],
which consists of 6 different tasks (Rule shift cards, Ac-
tion program, Key search, Temporal judgment, Zoo map
and the Six elements) and provides an ecological evalua-
tion of several of the executive functions’ components,
including planning, evaluative judgment and goal-ori-
ented behaviour. Although first developed for the assess-
ment of brain-damaged patients, the BADS has been val-
idated in a large group of patients with various neurolog-
ical disorders including MS [22]. Finally, the Trail Making
Test (TMT) [23] was chosen to assess selective attention
and processing speed. Impaired patients were those who
failed in at least one neuropsychological measure. 
Behaviour and functional abilities
A psychiatric interview using a French questionnaire
(Questionnaire de Santé du Patient; QSP) was conducted
to search for the presence of mood disorders according to
the DSM-IV diagnostic criteria [24]. Mood modifications
were also quantified by means of the Hospital Anxiety
and Depression scale (HAD) [25]. Fatigue was assessed
using the Fatigue Assessment Instrument (FAI) [26], a 29-
item auto-evaluation scale validated in several pathologi-
cal conditions including MS. A score for the severity of
fatigue was calculated from the 11 FAI items dealing with
severity of symptoms. Handicap was evaluated using the
London Handicap Scale (LHS) [27], which assesses the 6
items of handicap: mobility, orientation, occupation,
physical independence, social integration and economic
self-sufficiency; each area was rated on a 6-point scale to
provide a global score. Finally, QoL was assessed using
the SEP-59 [28], a validated French version of the
MSQOL-54 [29] which contains 15 dimensions of daily
living validated by factor analysis [28].
Statistical analysis
We used the chi2 test to compare the distributions of
categorical variables between two groups, e.g. with and
without cognitive deficits. Means of continuous variables
were compared using the t test, and the Wilcoxon rank
test served to compare the mean number of relapses. A
logistic regression, including QoL, depression, anxiety,
fatigue and handicap scores, was used to determine the
factors linked to impaired cognition. The significance of
these factors was assessed using the Wald test and the
likelihood ratio test. The goodness of the model was as-
sessed by the Lemeshow test. 
Patients and methods
Results
Demographic and clinical data 
Of 127 patients tested, 106 MS patients were
finally retained for analysis. Twenty-one CIS pa-
tients were excluded as the diagnosis of MS was
not confirmed during the follow-up period deter-
mined by the time necessary to complete this
transectional study. The demographic and clinical
data of the 106 MS patients are summarised in
table 1. The group included a high proportion of
women (70%), reflecting the sex ratio convention-
ally observed in the general MS population. 
Concerning mood variables, 43 patients
(47.3%) had a significant score for anxiety and 17
(18.7%) for depression on the HAD, although
only 9 of them had a diagnosis of mood disorder
according to the DSM-IV criteria. All these 9 pa-
tients were treated with antidepressive drugs.
Forty-nine patients (53.3%) reported a high fa-
tigue score on the FAI severity subscale. Of these,
6 were treated with selective serotonin reuptake
inhibitors and 4 with amantadine. The prevalence
of fatigue was 63% among patients receiving in-
terferon-b1a or 1b vs 43% in those untreated (p =
0.06). Moreover, fatigue was significantly associ-
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ated with anxiety (HAD-A; p = 0.01) and with de-
pression (HAD-D; p = 0.02). Regarding func-
tional abilities, the mean handicap score was
8.6±3.3 (the maximum score corresponding to the
severest handicap = 36) and the mean SEP-59
total score was 46.3±11.1 (the maximum score
corresponding to the lowest QoL = 100) (table 2). 
Prevalence and nature of cognitive deficits
Thirty-one MS patients (29.3%) presented
cognitive deficits (table 3). Memory impairment
was the most frequent (23.6% of patients, n = 25),
followed by attentional (10.4%, n = 11) and exec-
utive deficits (5.7%, n = 6). For 23 patients, cogni-
tive impairment was mild, with only one cognitive
domain being 2 SD below the appropriate mean
for the test. Eight patients were more severely im-
paired, having deficits for two cognitive domains
(e.g. both memory and attention).
The prevalence of cognitive deficits predomi-
nated in RRMS (32%), as compared with MRI-
proven MS (26.3%) and with CIS patients who
confirmed diagnosis after inclusion (20%). How-
ever, this trend was not statistically significant, a
fact consistent with our requirement of a homo-
geneous early MS patients sample.
Comparison of MS patients with and without
cognitive deficits
Demographic and clinical variables
MS patients with and without cognitive
deficits were comparable in terms of age (36 vs 33
years; p = 0.1), gender (64% vs 72% females; p =
0.4) and education (16% vs 28% highly educated;
p = 0.3). They were also similar for disease dura-
tion (2.5 vs 2.6 years; p = 0.6), mean number of re-
lapses since MS onset (2.5 vs 2.1; p = 0.1) and
EDSS score (1.8 vs 1.7; p = 0.7). The proportion
of patients receiving interferon-b1a and 1b was
comparable in the two groups (50% vs 49%; p =
0.9). 
Mood disorders, fatigue, handicap and QoL
The prevalence of mood disorders and fa-
tigue was significantly higher in patients with
cognitive deficits than in those without (anxiety
63% vs 41%, p = 0.05; depression 37% vs 11%, p
= 0.004; fatigue 70% vs 46%, p = 0.03). The LHS
(10.4 [SD 4.1] vs 7.8 [SD 2.6]) and QoL scores
(52.0 [SD 9.8] vs 43.8 [SD 10.7]) also differed sig-
nificantly between patients with cognitive disor-
ders and those without (p <0.001 for both scales).
More specifically, memory deficits were associ-
ated with a lower QoL (51.9 [SD 10.7] in patients
Gender (women/men) 74 / 32
Mean age (years ± SD) 34.1±9.3
Schooling ≤12 years (minimum compulsory school; %) 13.2
≥12 years (secondary school; %) 62.3
Academic background (university; %) 24.5
MS phenotype RRMS (n) 72
MS confirmed by MRI (n) 19
Possible MS1 (n) 15
MS mean duration [years (SD)] 2.6 (1.8)
Number of relapses since MS onset [mean (SD)] 2.2 (1.4)
EDSS score [mean (SD)] 1.8 (0.4)
Immunomodulatory therapy Interferon-b 1a or 1b 52
No treatment 54
1 MS was confirmed by a second relapse after inclusion in the study
Scales Mean Range % of patients with Normative
score ± SD (median) abnormal scores cut-off values
Mood HAD-A 7.5±3.7 0–16 (7) 47.3 ≥8
HAD-D 4.2±3.4 0–15 (3) 16.7 ≥8
Fatigue FAI severity 4.2±1.6 1.1–6.7 (4.5) 53.3 >4.26
QoL SEP-59 total 46.3±11.1 25–73 (46.5) - NA (maximum
score possible score: 100)
Handicap LHS total 8.6±3.3 0–18 (7) - NA (maximum
score possible score: 36)
HAD, Hospital Anxiety and Depression scale; FAI, Fatigue Assessment Instrument; LHS, London Handicap Scale; NA, not available.
Remark: Statistics were computed on the available cases for the specific variables (n = 91 for HAD-A and HAD-D, n = 92 for FAI, 
LHS and SEP-59).
Table 1
Demographic and
clinical data at inclu-
sion for the 106 early
MS patients retained
for analysis.
Table 2
MS patients’
 performance 
in  behavioural
 assessment.
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with memory deficits vs 44.5 [SD 10.6] in those
without; p = 0.006). In the memory task, delayed
recall was associated with a lower QoL (52.1 [SD
8.4] in patients with impaired delayed recall vs
45.1 [SD 11.2] in those with normal delayed re-
call; p = 0.02), whereas learning capacities were
not (51.1 [SD 13.6] in patients with impaired
learning vs 45.6 [SD 10.6] in those with normal
learning; p = 0.1). Since the prevalence of deficits
in attention or executive tasks was low, a specific
association between these cognitive domains and
QoL was not further investigated.
Mood disorders, fatigue, handicap and QoL
were associated with the presence of cognitive
deficits. Furthermore, the complete matrix of
odds ratio showed that each factor was associated
with any of the other individual factors (data not
shown).
Logistic model to predict the prevalence of cognitive
deficits according to MS patients’ characteristics
Table 4 shows the prevalence of cognitive
deficits according to the presence or the absence
of mood disorders, fatigue, significant handicap or
low QoL. The univariate odds ratio (OR) was sig-
nificantly >1 for each factor (table 4). For mood
disorders, OR = 2.7 (95%CI = 1.1; 7.0), for fatigue
OR = 2.8, (95%CI = 1.1; 7.2) and for handicap
OR = 5.7 (95%CI = 2.0; 16.5). Cognitive impair-
ment had a strong link with low QoL (OR = 6.3,
95%CI [2.1; 18.7]). A first multivariable logistic
regression with cognitive deficits as a dependent
variable, and handicap, mood disorders and fa-
tigue as independent variables, showed that, after
adjustment for handicap, mood disorders and fa-
tigue were no longer linked to cognitive deficits
(table 4, model 1). When QoL was added to hand-
icap in the analysis, OR for mood disorders and
fatigue became non-significant, indicating that
QoL alone contained the entire information – in-
cluding those of the other factors – for predicting
the presence of cognitive deficits (table 4, model
2). 
The sample size was rather small to accom-
modate 4 factors. However, OR were fairly simi-
lar when models including fewer variables were
tested. Goodness of fit of both models has been
successfully checked. 
Scales Mean Range % of patients with Normative
score ± SD (median) abnormal scores cut-off values
Memory (RAVLT)
Learning condition 57.0±8.1 39–72 (58) 12.3 <44
Delayed recall 12.6±2.1 6–15 (13) 16.0 <10
Overall deficits 23.6
Executive functions (BADS)
Rule shift cards test 3.3±0.8 0–4 4.0 <2
Action programme test 3.9±0.3 3–4 0 <2.73
Key search test 3.2±1.0 1–4 0 <–0.04
Temporal judgment 2.8±0.8 0–4 2.0 <0.33
Zoo map test 3.2±0.9 0–4 1.0 <0.18
Six elements test 3.7±0.6 1–4 1.0 <1.92
BADS profile score 20.1±2.5 10–24 (21) 2.8 <11
Overall deficits 5.7
Attention
TMT-A (time) 32.4±12.0 sec 16–83 (30) 1.9 >74 sec
TMT-A (errors) 0.07±0.35 0–3 (0) 4.7 >1
TMT-B (time) 72.2±28.0 sec 32–180 (66) 6.6 >131 sec
TMT-B (errors) 0.24±0.7 0–4 (0) 3.8 >2
Overall deficits 10.4
RAVLT, Rey’s Auditory Verbal Learning Test; BADS, Behavioural Assessment of the Dysexecutive Syndrome;
TMT, Trail Making Test.
Cognitive deficits Univariate OR Adjusted OR Adjusted OR  
(95%CI) Model 1 Model 2
Presence (%) Absence (%)
Mood disorders 40 20 2.7 (1.1;7.0) 1.9 (0.7;5.2) 1.0 (0.3;3.4)
Fatigue 39 19 2.8 (1.1;7.2) 1.4 (0.5;4.2) 1.1 (0.3;3.5)
Handicap (LHS >10) 60 21 5.7 (2.0;16.5) 3.8 (1.1;12.8) 2.5 (0.7;8.8)
Low QoL (MSEP >45) 46 12 6.3 (2.1;18.7) – 4.2 (1.0;17.2)
Table 3
MS patients’ 
performance in cog-
nitive assessment.
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Table 4
Predictive prevalence
of cognitive deficits
according to each of
the 4 factors (mood
disorders, fatigue,
degree of handicap
and QoL) using uni-
variate and multivari-
ate regression. In
univariate analysis,
cognitive impairment
showed the strongest
link with low QoL (OR
= 6.3, 95%CI [2.1;
18.7]).
496-501 Sim 11874-07.qxp  6.9.2007  13:56 Uhr  Seite 499
500Cognition impairment in early MS
Although the cognitive profile of MS patients
has been widely documented in more advanced
phases of the disease, studies focused on the initial
phase of MS have often included populations that
were heterogeneous in terms of phenotype, dis-
ease duration and disability [9–11]. Using the re-
vised McDonald criteria [17, 18], we tested a large
homogeneous group of MS patients with both a
short disease duration and a minor neurological
disability. The inclusion of CIS patients, who
were then excluded from the analysis if MS diag-
nosis was not confirmed by the end of the study,
allowed evaluation of MS patients at the earliest
clinically detectable stage of MS.
Twenty-nine percent of our cohort presented
cognitive deficits, but the impairment was mild,
with generally only one single domain involved.
The prevalence of cognitive deficits was compara-
ble in RRMS, MRI-confirmed MS, and CIS pa-
tients confirmed as MS after inclusion. Most in-
terestingly, a significant frequency of cognitive
deficits was already present in the latter group
(20%), suggesting that cognitive deficits may ap-
pear even before MS could be confirmed. In this
homogeneous early MS group, the frequency of
cognitive deficits was not influenced by disease
duration, neurological disability or interferon-b
treatment. We presented evidence that impaired
cognition may be an initial symptom in MS pa-
tients without neurological disability, but we also
found that it was associated with the presence of
mood disorders, handicap and fatigue. This sug-
gests that, at least at the early stage of MS, cogni-
tive efficiency is closely linked to affective factors,
and it confirms a complex interplay between fa-
tigue, mood disorders, functional abilities and
cognition in MS. More specific social-behavioural
changes linked to cognitive deficits were not
measured.
Compared with other studies [14–16], we de-
tected a low prevalence of depressive symptoms
whereas anxiety was frequent. The fact that we in-
cluded only MS patients with a short disease du-
ration and minor neurological disability may ex-
plain this discrepancy, as well as the fact that the
scales we used were different from previous stud-
ies. We also confirmed a high prevalence of fa-
tigue, commonly quoted as one of the most dis-
abling symptoms of MS [12, 13] even at an early
stage. Mood disorders and fatigue were closely as-
sociated, showing that these symptoms may over-
lap in MS. Given that the depression and anxiety
scale we used (HAD) did not include items re-
garding neurovegetative complaints (possibly
overlapping with MS symptoms and fatigue) and
included only a single item evaluating mental effi-
ciency, the overlap between mood disorders and
fatigue was probably only marginally influenced
by the questionnaires we used to measure these
symptoms. 
In accordance with previous reports, the most
frequent cognitive impairment concerned effort-
ful learning capacities, whereas processing
speed/attention and executive functions were bet-
ter preserved. Specific attentional impairment was
only rarely found in our group, though we did not
specifically focus on sustained attention, which is
known to be frequently impaired in the MS
process. The high prevalence of learning difficul-
ties in our population is probably due in part to
the fact that the RAVLT is a demanding task also
sensitive to “effortful” attentional capacities not
assessed here. Our results showed a link between
cognitive impairment, particularly memory
deficits, and the functional handicap and QoL re-
ported by MS patients in daily living. Using a
multivariate model including handicap, mood dis-
orders and fatigue, we found that low QoL was an
associated factor of cognitive deficits that summa-
rized all the information contained in the other
factors. 
In conclusion, cognitive impairment is an
early MS-related deficit but it remained relatively
mild and still with a low prevalence (29.3%) in
our cohort. Despite the fact that the topic has al-
ready been tackled by other groups in the litera-
ture, the clinical interest of our paper is double.
On the one hand, it provides arguments for spe-
cific difficulties in the early phase of MS in deal-
ing with “effortful” cognitive tasks rather than
with individual functions (such as attention, plan-
ning or learning). On the other hand, it points to
the importance for at least some MS patients of
adapting their mental activity from the early
symptoms of the disease onwards. Moreover, the
results of this study highlight the importance of
cognitive tests among patients in the early phase
of MS when disability scores are still low, and
point to the importance for clinicians of looking
for cognitive difficulties, given the impact a cog-
nitive impairment may have on MS patients’ so-
cial and professional abilities. Cognitive efficiency
was also associated in a complex interplay with
non-neurological factors such as mood disorders,
fatigue and handicap, whereas its association with
QoL was major. This low prevalence of cognitive
deficits may have been partly influenced by
methodological factors, since we performed a
neuropsychological assessement aimed at evaluat-
ing the 3 cognitive domains classically impaired in
MS, in contrast to other studies using full-length
neuropsychological batteries [6, 10]. Moreover,
our study did not include a control group of
healthy subjects and the use of standardised nor-
mative data may have contributed to lowering the
sensitivity of the assessement. However, we were
still able to evidence cognitive impairment at the
earliest stage of the disease, that is, in CIS patients
whose diagnosis was confirmed only after inclu-
sion in the study (20%). To investigate the ques-
Discussion
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tion whether such early cognitive impairment
could be predictive of MS evolution, we plan to
assess our cohort longitudinally. 
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